Flagship Harbor Advisors LLC acquired a new position in shares of Sanofi SA (NYSE:SNY) in the second quarter, HoldingsChannel reports. The firm acquired 11,447 shares of the company’s stock, valued at approximately $458,000.

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. Huntington National Bank lifted its stake in shares of Sanofi by 24.9% during the 2nd quarter. Huntington National Bank now owns 6,037 shares of the company’s stock worth $242,000 after purchasing an additional 1,202 shares during the last quarter. Advisor Partners LLC lifted its stake in shares of Sanofi by 23.7% during the 2nd quarter. Advisor Partners LLC now owns 6,503 shares of the company’s stock worth $260,000 after purchasing an additional 1,245 shares during the last quarter. Pekin Singer Strauss Asset Management IL lifted its stake in shares of Sanofi by 3.6% during the 2nd quarter. Pekin Singer Strauss Asset Management IL now owns 38,355 shares of the company’s stock worth $1,535,000 after purchasing an additional 1,315 shares during the last quarter. Steward Partners Investment Advisory LLC lifted its stake in shares of Sanofi by 8.3% during the 2nd quarter. Steward Partners Investment Advisory LLC now owns 18,344 shares of the company’s stock worth $734,000 after purchasing an additional 1,401 shares during the last quarter. Finally, Zions Bancorporation lifted its stake in shares of Sanofi by 8.7% during the 2nd quarter. Zions Bancorporation now owns 19,340 shares of the company’s stock worth $774,000 after purchasing an additional 1,544 shares during the last quarter. Hedge funds and other institutional investors own 7.54% of the company’s stock.

Shares of NYSE:SNY opened at $43.34 on Thursday. Sanofi SA has a 1 year low of $37.43 and a 1 year high of $50.65. The stock has a market cap of $105.57 billion, a P/E ratio of 13.85, a price-to-earnings-growth ratio of 2.19 and a beta of 0.85. The company has a current ratio of 1.22, a quick ratio of 0.85 and a debt-to-equity ratio of 0.40.

Sanofi (NYSE:SNY) last announced its earnings results on Tuesday, July 31st. The company reported $0.74 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.72 by $0.02. Sanofi had a return on equity of 23.77% and a net margin of 10.29%. The company had revenue of $8.18 billion for the quarter, compared to analyst estimates of $8.27 billion. During the same period in the prior year, the company posted $1.35 EPS. The firm’s quarterly revenue was down 5.6% compared to the same quarter last year. research analysts expect that Sanofi SA will post 3.15 EPS for the current fiscal year.

SNY has been the subject of a number of analyst reports. ValuEngine upgraded Sanofi from a “strong sell” rating to a “sell” rating in a research note on Friday, July 20th. Zacks Investment Research upgraded Sanofi from a “sell” rating to a “hold” rating in a research note on Tuesday, July 3rd. TheStreet upgraded Sanofi from a “c+” rating to a “b” rating in a research note on Thursday, July 12th. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Sanofi in a research report on Tuesday, July 31st. Finally, Argus upped their target price on Sanofi from $46.00 to $48.00 and gave the company a “buy” rating in a research report on Friday, August 24th. Three analysts have rated the stock with a sell rating, six have issued a hold rating and six have assigned a buy rating to the company. Sanofi currently has an average rating of “Hold” and an average target price of $49.00.

In related news, major shareholder Sanofi sold 104,552 shares of the company’s stock in a transaction dated Thursday, September 6th. The stock was sold at an average price of $406.68, for a total transaction of $42,519,207.36. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Corporate insiders own 1.00% of the company’s stock.

Sanofi Company Profile

Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an oral immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis.

Featured Story: Market Capitalization – What it Means for Investors

Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi SA (NYSE:SNY).

Institutional Ownership by Quarter for Sanofi (NYSE:SNY)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.